Table 1.

Biological evaluation in vitro.

		IC50 value (μM)
Products	NO releasing activity (%)a	α-Glucosidase inhibitory activityb	AGEs inhibitory activityc	ALR2 inhibitory activityd
DMSO
Pterostilbene		>1000	1.99 ± 0.51**	>1000
Resveratrol		241.53 ± 16.98**	0.83 ± 0.21**	17.02 ± 0.31
3a	1.029 ± 0.009**	>1000	2.90 ± 0.09**	>1000
3b	1.359 ± 0.034**	>1000	2.39 ± 0.11**	>1000
3c	1.391 ± 0.050**	83.12 ± 16.21**	1.49 ± 0.20**	299.25 ± 22.62**
3d	0.896 ± 0.004**	>1000	1.39 ± 0.16**	10.03 ± 0.15
3e	0.900 ± 0.006**	178.74 ± 5.76**	1.05 ± 0.25**	8.18 ± 0.33
7a	0.922 ± 0.020**	>1000	1.29 ± 0.04**	>1000
7b	1.000 ± 0.004**	>1000	0.97 ± 0.16**	>1000
7c	1.056 ± 0.023**	163.40 ± 14.20**	0.68 ± 0.07**	121.13 ± 13.28**
SNP	6.825 ± 0.187
Acarbose		0.05 ± 0.003
AG			282.81 ± 8.52
Quercetin				3.71 ± 0.29

Each value represents the mean ± SD (n = 3).

^aPercentage of NO released relative to a theoretical maximum release of 1 mol NO/mol of test compound; determined by Griess reagent in the presence of 5 mM l-cysteine, at pH 7.4.

^bThe concentration required for a 50% inhibition in the optical density of PNP (p-nitrophenol) at 405 nm relative to DMSO. IC₅₀ values were calculated from the dose inhibition curve.

^cThe concentration required for a 50% inhibition of the fluorescence intensity of AGE relative to 0.1% DMSO, IC₅₀ values were calculated from the dose inhibition curve.

^dThe concentration required for a 50% inhibition of the decrease in the optical density of NADPH at 340 nm relative to DMSO. IC₅₀ values were calculated from the dose inhibition curve.

^**p < .01 significantly different ANOVA followed by Dunnett’s t-test for comparison with standard.